Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on age-related disorders of the central nervous system and retina. Its lead candidate is zervimesine, an oral small molecule also known as CT1812.
Three current, attributable analyst price targets form the basis of the central target. H.C. Wainwright's Ram Selvaraju reiterated a Buy with a $3.00 target in October 2026, citing a new composition-of-matter patent on a crystalline form of zervimesine. Chardan Capital's Daniil Gataulin maintained a Buy with a $4.00 target in May 2026. B. Riley Securities' William Woods reiterated a Buy with a $3.00 target in November 2025, after raising it from $2.00. The average of $3.00, $3.00, and $4.00 is about $3.33, rounded to a clean central target of $3.30, with a low-to-high range of $3.00 to $4.00.
All three published ratings are Buy, but the sample is small and the range is wide — roughly 33% between the low and high targets — reflecting genuine disagreement about how to discount the probability of clinical success. Analysts base their targets primarily on risk-adjusted discounted-cash-flow models for zervimesine in DLB and Alzheimer's disease, and none treats the figure as a guarantee.
With shares trading near $0.76 and a market capitalization of roughly $72 million, CGTX is a micro-cap, pre-revenue biotech. Reaching $3.30 from current levels would require a gain of approximately 330%, which must be described as a very large move rather than a modest or moderate one.
The path toward the target runs almost entirely through clinical and regulatory milestones. The company has aligned with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 trial of zervimesine in DLB psychosis, with the NPI-2 neuropsychiatric scale as the primary endpoint. A Phase 2 START study in early Alzheimer's disease is fully enrolled, with results expected in 2027. Because the company generates no meaningful revenue, its valuation is driven by the market's changing assessment of these development programs rather than earnings multiples or cash flow.
The most important supportive factors are clinical and regulatory. The FDA's alignment on patient selection, dose, duration, and endpoints for the Phase 3 DLB program removes a layer of uncertainty and builds on Phase 2 SHIMMER data that the company says showed zervimesine slowed symptom progression. A newly granted U.S. patent on an improved crystalline form extends potential exclusivity to 2045, with up to five years of possible extension, strengthening long-term commercial visibility.
There is also no approved therapy that slows DLB progression, so a successful registrational program would address a large unmet need affecting an estimated 1.4 million Americans. A stronger balance-sheet position, such as a partnership or non-dilutive funding, and positive updates on the Alzheimer's START trial, could further shift investor sentiment and support the stock's valuation.
The principal risk is binary clinical-trial failure. If the pivotal DLB study or the START Alzheimer's readout disappoints, the investment thesis could weaken sharply. As a pre-revenue company, Cognition Therapeutics (CGTX) also faces financing risk: its cash runway extends only into 2027, and raising additional capital could dilute existing shareholders.
Broader competitive and regulatory risks also apply, including execution risk in scaling up manufacturing of the new crystalline form and the general difficulty of developing treatments for neurodegenerative diseases. Finally, as a sub-$1 micro-cap with a beta near 1.8, the stock is highly volatile and sensitive to sector-wide swings in biotechnology sentiment.
The stock's 52-week range of roughly $0.55 to $1.83 illustrates its volatility and the scale of the move implied by a $3.30 target, which sits well above the stock's recent trading history. The $0.55 area represents a notable long-term support level, while the $0.55–$1.00 zone has been the stock's primary range in recent months. A sustained move above the psychologically significant $1.00 level would be an early sign of changing market structure, though no technical level currently in sight corresponds to the analyst targets, which are fundamentally driven by drug-development milestones rather than chart levels.
Analyst price targets typically reflect a 12-month research horizon, and the targets cited here are stated as 12-month objectives. The most important upcoming items are the initiation of the pivotal DLB program, expected around mid-2027; the Phase 2 START Alzheimer's readout, expected in 2027; further FDA interactions; and any financing or partnership announcements. Investors should also monitor analyst target revisions, which are frequent for clinical-stage biotechs as data and regulatory feedback arrive.
For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor positions, and spot shifting trends more efficiently than manual scanning. Traders interested in complementing their research with automated, data-driven signals can explore the AI Daily Buy/Sell Signals feature as part of a broader toolkit.
Can CGTX reach $3.30? The target is the average of three analyst price targets — $3.00, $3.00, and $4.00 — and requires a gain of roughly 330% from current levels, a very large move for a micro-cap biotech. The bull case rests on FDA alignment on a pivotal DLB trial, encouraging Phase 2 data, and extended patent protection, while the bear case centers on binary clinical risk, a limited cash runway, and potential dilution. Analysts agree on direction but not magnitude, as shown by the $3.00-to-$4.00 spread. The outcome will be determined chiefly by clinical data and financing developments rather than short-term price action, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CGTX has been loosely correlated with RCKT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CGTX jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To CGTX | 1D Price Change % | ||
|---|---|---|---|---|
| CGTX | 100% | +1.06% | ||
| RCKT - CGTX | 41% Loosely correlated | +1.22% | ||
| SYRE - CGTX | 38% Loosely correlated | +2.24% | ||
| MGX - CGTX | 37% Loosely correlated | +8.04% | ||
| IMVT - CGTX | 36% Loosely correlated | +3.72% | ||
| SANA - CGTX | 36% Loosely correlated | -5.76% | ||
More | ||||